Biosensors for bladder cancer diagnosis

April 17, 2018, University of Bath
Biosensors for bladder cancer diagnosis
Credit: Lightspring, Shutterstock

Cancer constitutes one of the leading causes of mortality worldwide. As early diagnosis is paramount to improved clinical outcome and survival, sensitive diagnostics capable of detecting cancer-related molecules are necessary.

Despite technological advances, traditional methodologies such as ELISA assays are routinely used in clinical practice for diagnosis of cancer. However, these are time-consuming and suffer from low sensitivity, necessitating alternative clinically relevant solutions for early screening of individuals at high risk of cancer.

Scientists with the EU-funded BlaC E-assay project proposed to develop biosensors, devices broadly used in biomedical applications to detect specific molecules present in biological samples. To detect the target molecule, biosensors employ bioreceptors such as antibodies, oligonucleotides or enzymes that generate a signal such as heat, light or pH change. Via a transducer, the bio-recognition event is converted into an electrical or optical signal that is proportional to the levels of the measured molecule.

Electrochemical biosensors are widely used for at-home monitoring of in diabetic patients as well as environmental monitoring, food safety and drug discovery. The idea behind BlaC E-assay was to generate a reliable point-of-care (POC) diagnostic system for cancer that integrated microfluidic and electrochemistry technologies.

A novel biosensor for biomarker detection

Existing electrochemical sensors promise easy operation, accuracy and , but often suffer from issues such as background signals, non-specificity and -selectivity in clinical samples. Since selectivity is the most important feature of a diagnostic , scientists carefully considered the biorecognition molecules of choice.

"The BlaC E-assay system is a generic platform and can be adapted to a variety of diagnostic tests, as long as there is a biorecognition element available such as an antibody or a DNA aptamer,″ explains project co-ordinator Dr. Estrela. "Our efforts concentrated on the detection of multiple protein biomarkers of bladder and breast cancer,″ he continues. To overcome the instability of antibodies, scientists looked for alternative bio-recognition elements such as synthetic oligonucleotide aptamers. These come in the form of single-strand DNA or RNA and are designed to bind to specific targets such as proteins.

The BlaC E-assay benchtop device comprises separate assay and detection chambers with innovative surface chemistry and microfluidic design, combined with electrochemical detection techniques. Although, not tested in a clinical environment, commercial blood serum samples spiked with the biomarkers in question showed very promising results.

The BlaC E-assay biosensor was precise and generated reproducible results. Researchers further addressed the sensitivity and resolution of the device. In a clinical setting, biosensors are required to demonstrate high sensitivity of molecule detection at ng/ml concentrations. In addition, they must exhibit sufficient resolution by proportionally responding to analyte levels.

The future of biosensors in disease diagnosis

In spite of extensive research over the past 50 years, commercially available biosensors are extremely limited with the exception of lateral flow pregnancy tests and electrochemical glucose biosensors. Issues with commercial clinical application include difficulties in bringing teams from different disciplines together, translating academic research into commercially viable prototypes and overcoming complex regulatory issues.

With novel nanomaterials and microfabrication technologies, the future of biosensors in biomedical diagnosis certainly looks hopeful. The application niche of disease diagnosis is continuously expanding and advents in biosensor development will undoubtedly aid the diagnosis of many diseases. Following proof-of-principle, Dr. Estrela hopes to obtain additional funding to construct a device prototype that can be miniaturised and promoted to industry for commercialisation.

Explore further: Developing biosensor devices for better cancer diagnosis

Related Stories

Developing biosensor devices for better cancer diagnosis

August 17, 2016
Diagnosing cancer early on can greatly improve a patient's prognosis. Biopsies and screening are the most common and accurate means currently used to identify cancer markers in the blood. But samples have to be sent to central ...

Fast detection of Dengue virus with new diagnostic

March 15, 2016
Fast detection for Dengue virus is possible based on an innovative label free immunosensor. The novel immunosensor with antibody-nanoparticle hybrid design offers high selectivity and sensitivity for Dengue virus NS1 biomarker ...

Scientists develop ultra-sensitive test that detects diseases in their earliest stages

May 27, 2012
Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.